Skip to main content
Fig. 1 | BMC Research Notes

Fig. 1

From: CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer

Fig. 1

CITED1 is expressed in cell lines of the ER+ luminal breast cancer subtype and correlates with tamoxifen response in vivo. A GOBO database of breast cancer cell lines showing relative expression of CITED1 mRNA ordered by tumour molecular subtypes representation. Luminal—orange, Basal A—light blue, Basal B—blue *Misclassified melanoma cell line, MDAMB435 [36]. B CITED1 protein expression is shown in breast cancer cell lines representing the different tumour molecular subtypes. β-actin is used as a loading control. C CITED1 expression in the various molecular subtypes represented in the GOBO breast tumour dataset. D CITED1 expression in ER+ and ER− tumours in the GOBO tumour dataset. E Survival analysis showing distant metastasis-free survival (DMFS) in patients with breast cancer treated with tamoxifen (TAM). Patients were classified into 3 groups according to expression: high CITED1—orange, medium CITED1—light blue, low CITED1—blue. F Survival analysis for the cohort of ER+/LN− patients treated with tamoxifen (TAM). The number of patients in each group at diagnosis is indicated as n

Back to article page